Processing

Please wait...

PATENTSCOPE will be unavailable a few hours for maintenance reason on Tuesday 25.01.2022 at 12:00 PM CET
Settings

Settings

Goto Application

Offices all Languages Stemming false Single Family Member true Include NPL false

Save query

A private query is only visible to you when you are logged-in and can not be used in RSS feeds

Query Tree

Refine Options

Offices
All
Specify the language of your search keywords
Stemming reduces inflected words to their stem or root form.
For example the words fishing, fished,fish, and fisher are reduced to the root word,fish,
so a search for fisher returns all the different variations
Returns only one member of a family of patents
Include Non-Patent literature in results

Full Query

IC:C12N15/00

Side-by-side view shortcuts

General
Go to Search input
CTRL + SHIFT +
Go to Results (selected record)
CTRL + SHIFT +
Go to Detail (selected tab)
CTRL + SHIFT +
Go to Next page
CTRL +
Go to Previous page
CTRL +
Results (First, do 'Go to Results')
Go to Next record / image
/
Go to Previous record / image
/
Scroll Up
Page Up
Scroll Down
Page Down
Scroll to Top
CTRL + Home
Scroll to Bottom
CTRL + End
Detail (First, do 'Go to Detail')
Go to Next tab
Go to Previous tab

Analysis

1.WO/2022/011452USE OF PAPERCLIP RNA STRUCTURE TO INHIBIT TARGET GENE EXPRESSION
WO 20.01.2022
Int.Class C12N 15/113
CCHEMISTRY; METALLURGY
12BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
NMICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
15Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
09Recombinant DNA-technology
11DNA or RNA fragments; Modified forms thereof
113Non-coding nucleic acids modulating the expression of genes, e.g. antisense oligonucleotides
Appl.No PCT/CA2021/050911 Applicant UNIVERSITY OF MANITOBA Inventor WHYARD, Steve
Described herein is a "paperclip" structured dsRNA (pcRNA) that has two closed ends (Figure 1), and was developed and tested for its ability to enter insect cells and induce RNAi. While conventional dsRNAs, with their two collinear RNA strands, enter insect cells by clathrin-mediated endocytosis, the pcRNAs can enter cells by a clathrin-independent mechanism. The new structured dsRNA can be used to deliver dsRNA to insects that either develop resistance through alterations to their conventional uptake mechanisms and to insects that are naturally refractory to dsRNAs, including lepidopteran pests.
2.WO/2022/012097ANTI-HUMAN MSLN ANTIBODY AND MSLN-TARGETING IMMUNE EFFECTOR CELL
WO 20.01.2022
Int.Class C07K 16/30
CCHEMISTRY; METALLURGY
07ORGANIC CHEMISTRY
KPEPTIDES
16Immunoglobulins, e.g. monoclonal or polyclonal antibodies
18against material from animals or humans
28against receptors, cell surface antigens or cell surface determinants
30from tumour cells
Appl.No PCT/CN2021/086067 Applicant HRAIN BIOTECHNOLOGY CO., LTD. Inventor HUANG, Fei
The present invention provides an anti-human MSLN-specific antibody and an MSLN-targeting immune effector cell. Also provided is an MSLN-targeting chimeric antigen receptor modified T-cell prepared using the antibody and a use thereof.
3.WO/2022/012682CD22 BINDING MOLECULES AND USES THEREOF
WO 20.01.2022
Int.Class C07K 16/28
CCHEMISTRY; METALLURGY
07ORGANIC CHEMISTRY
KPEPTIDES
16Immunoglobulins, e.g. monoclonal or polyclonal antibodies
18against material from animals or humans
28against receptors, cell surface antigens or cell surface determinants
Appl.No PCT/CN2021/106891 Applicant NANJING LEGEND BIOTECH CO., LTD. Inventor FAN, Xiaohu
The present disclosure provides single domain antibodies that bind to CD22, and chimeric antigen receptors comprising same. Further provided are engineered immune effector cells (such as T cells) comprising the chimeric antigen receptors. Pharmaceutical compositions, kits and methods of treating a disease or disorder are also provided.
4.WO/2022/012531METHOD FOR PREPARING MODIFIED IMMUNE CELL
WO 20.01.2022
Int.Class C12N 15/90
CCHEMISTRY; METALLURGY
12BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
NMICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
15Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
09Recombinant DNA-technology
87Introduction of foreign genetic material using processes not otherwise provided for, e.g. co-transformation
90Stable introduction of foreign DNA into chromosome
Appl.No PCT/CN2021/106007 Applicant CURE GENETICS CO., LTD Inventor JIA, Luying
A method for preparing a modified immune cell. The modification comprises the following steps: a) reducing the expression and/or activity of a Fas protein in the immune cell, and b) increasing the expression and/or activity of a FasL protein in the immune cell. Thus, compared to an immune cell which is not subjected to the modification, the expression and/or activity of the Fas protein in the modified immune cell are reduced or eliminated, and the expression and/or activity of the FasL protein in the modified immune cell are increased.
5.WO/2022/012591ENGINEERED IMMUNE CELL FOR ALLOTRANSPLANTATION
WO 20.01.2022
Int.Class C12N 5/10
CCHEMISTRY; METALLURGY
12BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
NMICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
5Undifferentiated human, animal or plant cells, e.g. cell lines; Tissues; Cultivation or maintenance thereof; Culture media therefor
10Cells modified by introduction of foreign genetic material, e.g. virus-transformed cells
Appl.No PCT/CN2021/106259 Applicant NANJING BIOHENG BIOTECH CO., LTD Inventor ZHOU, Yali
Provided is an engineered immune cell. The expressions of at least one MHC related gene and at least one NK activating receptor binding molecule are suppressed or silenced, so as to suppress the killing of the engineered immune cell by NK cells. Also provided are a pharmaceutical composition containing the engineered immune cell and a use of the engineered immune cell in preparation of drugs for treatment of cancer, infection, or autoimmune diseases.
6.WO/2022/012606ANTIBODIES BINDING C5 AND USES THEREOF
WO 20.01.2022
Int.Class A61K 39/395
AHUMAN NECESSITIES
61MEDICAL OR VETERINARY SCIENCE; HYGIENE
KPREPARATIONS FOR MEDICAL, DENTAL, OR TOILET PURPOSES
39Medicinal preparations containing antigens or antibodies
395Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum
Appl.No PCT/CN2021/106391 Applicant BIOSION INC. Inventor CHEN, Mingjiu
An isolated monoclonal antibody that specifically binds human C5, or the antigen-binding portion thereof. A nucleic acid molecule encoding the antibody or the antigen-binding portion thereof, an expression vector, a host cell and a method for expressing the antibody or the antigen-binding portion thereof are also provided. Further provided are a bispecific molecule, an immunoconjugate, a chimeric antigen receptor, an oncolytic virus and a pharmaceutical composition comprising the antibody or the antigen-binding portion thereof, as well as a treatment method using an anti-C5 antibody or the antigen-binding portion thereof.
7.WO/2022/012636GENETICALLY MODIFIED NON-HUMAN ANIMAL WITH HUMAN OR CHIMERIC IL17A AND/OR IL17F
WO 20.01.2022
Int.Class C12N 15/90
CCHEMISTRY; METALLURGY
12BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
NMICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
15Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
09Recombinant DNA-technology
87Introduction of foreign genetic material using processes not otherwise provided for, e.g. co-transformation
90Stable introduction of foreign DNA into chromosome
Appl.No PCT/CN2021/106559 Applicant BIOCYTOGEN PHARMACEUTICALS (BEIJING) CO., LTD. Inventor SHEN, Yuelei
Provided are genetically modified non-human animals that express a human or chimeric (e.g., humanized) IL17A and/or IL17F, and methods of use thereof.
8.WO/2022/012681MULTISPECIFIC CHIMERIC ANTIGEN RECEPTORS AND USES THEREOF
WO 20.01.2022
Int.Class C07K 19/00
CCHEMISTRY; METALLURGY
07ORGANIC CHEMISTRY
KPEPTIDES
19Hybrid peptides
Appl.No PCT/CN2021/106889 Applicant NANJING LEGEND BIOTECH CO., LTD. Inventor FAN, Xiaohu
The present disclosure provides chimeric antigen receptors targeting CD20, CD19 and/or CD22. Further provided are engineered immune effector cells (such as T cells) comprising the chimeric antigen receptors. Pharmaceutical compositions, kits and methods of treating a disease or disorder are also provided.
9.WO/2022/014196METHOD FOR PRODUCING THEANINE-PRODUCING MICROORGANISM
WO 20.01.2022
Int.Class C12N 15/52
CCHEMISTRY; METALLURGY
12BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
NMICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
15Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
09Recombinant DNA-technology
11DNA or RNA fragments; Modified forms thereof
52Genes encoding for enzymes or proenzymes
Appl.No PCT/JP2021/021367 Applicant TAIYO KAGAKU CO., LTD. Inventor KONDO, Yusuke
A non-natural microorganism that produces theanine from a carbon source, said microorganism containing a gene that encodes a protein having alanine decarboxylase activity and a gene that encodes a protein having γ-glutamylmethylamide synthetase activity or glutaminase activity. According to the present invention, theanine can be efficiently produced with the use of the novel microorganism.
10.WO/2022/015801KITS AND METHODS USEFUL FOR SEPARATING OLIGONUCLEOTIDES FROM MATRIX COMPONENTS
WO 20.01.2022
Int.Class C12N 15/10
CCHEMISTRY; METALLURGY
12BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
NMICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
15Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
09Recombinant DNA-technology
10Processes for the isolation, preparation or purification of DNA or RNA
Appl.No PCT/US2021/041552 Applicant WATERS TECHNOLOGIES CORPORATION Inventor DONEGAN, Michael
The present disclosure relates to kits and methods that may be used for removal of matrix components, including proteins and lipids, from one or more oligonucleotides. The method comprises loading a sample comprising one or more target oligonucleotides and one or more matrix components comprising proteins, lipids or both, onto a porous anion exchange sorbent comprising a bulk material and ionizable surface groups having a pKa in a range of about 8 to about 12, wherein target oligonucleotides are retained by the sorbent and matrix components are retained or un retained by the sorbent; flowing one or more washing solutions through the sorbent, wherein the washing solutions remove any retained matrix components from the sorbent while leaving the target oligonucleotides retained on the sorbent; and flowing one or more elution solutions though the sorbent, wherein the target oligonucleotides retained on the sorbent are released.